CARDIOVASCULAR JOURNAL OF AFRICA • Vol 24, No 5, June 2013
e14
AFRICA
one.
Clin Pharmacokinet
1984;
9
(2): 136–156.
5.
Ylitalo R. Bisphosphonates and atherosclerosis.
Gen Pharmacol
2000;
35
(6): 287–296.
6.
Lu PY, Hsieh CF, Tsai YW, Huang WF. Alendronate and raloxifene use
related to cardiovascular diseases: differentiation by different dosing
regimens of alendronate.
Clin Ther
2011;
33
(9): 1173–1179.
7.
John CA. Review of the cardiovascular safety of zoledronic acid and
other bisphonates for the treatment of osteoporosis.
Clin Ther
2010;
32
(3): 426–436.
8.
Lewiecki EM, Cooper C, Thompson E, Hartl F. Ibandronate does not
ıncrease risk of atrial fibrillation in analysis of pivotal clinical trials.
Int
J Clin Pract
2010;
64
(6): 821–826.
9.
Tanvetyanon T, Stiff PJ. Management of the adverse effects associated
with intravenous bisphosphonates.
Ann Oncol
2006;
17
(6): 897–907.
10. Gregoratos G,Abrams J, EpsteinAE, Freedman RA.ACC/AHA/NASPE
2002 guideline update for implantation of cardiac pacemakers and anti-
arrhytmia devices: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guideline (ACC/
AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines).
Circulation
2002;
106
(16): 2145
–
2161.
